Category: Uncategorized
CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Basel, 01 February 2019 CHMP recommends EU approval of Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis in a prospective intra-patient comparison First new class of medicine in nearly 20 years for people with severe haemophilia A without... Read more
A magical formula for neuron detection?
Leveraging ZEISS ZEN Intellesis and the digital microscopy platform APEER to automate segmentation workflows Knowledge After running the initial image through the workflow, you will receive a segmentation like this in our APEER account. Making sense of your imaging data traditionally was and mostly still is a tedious process. One of the baselines of any neuroscientific research:... Read more
QIAGEN provides status update on settlement mechanics of convertible notes
Notice to holders of the QIAGEN N.V. (the “Issuer”): 0.375% Senior Unsecured Convertible Notes due 2019 (the “2019 Notes”) – ISIN XS1046477235 0.875% Senior Unsecured Convertible Notes due 2021 (the “2021 Notes”) – ISIN XS1046477581 0.500% Senior Unsecured Convertible Notes due 2023 (the “2023 Notes”) – ISIN XS1682511818 1.000% Senior Unsecured Convertible Notes due 2024... Read more
A journey into a human kidney
ZEISS microscopes help uncover centuries old hidden secrets of human kidney stones Customer Story Knowledge Kidney stones are hard deposits made of minerals and salts that can form inside your kidneys. They have been ascribed no medical value at all, and doctors usually discard them right away. A research team led by Bruce Fouke, a... Read more
Bruker Comments on Block Trade Transaction
BILLERICA, Mass., Dec. 20, 2018 /PRNewswire/ — Bruker Corporation (NASDAQ: BRKR) has been advised that former board member, Mr. Joerg C. Laukien, has authorized a block sale of Bruker shares as part of his retirement planning and portfolio diversification. Joerg Laukien retired from the Bruker board of directors effective November 5, 2018. He is the brother... Read more
Notice Regarding Transfer of Mushroom Business
This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more
BD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL
FRANKLIN LAKES, N.J., Dec. 11, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This independent assessment evaluates corporate cybersecurity programs and policies to ensure that all medical devices developed by a company are built with robust... Read more
Announcing VACUETTE SAFELINK – A Safe Connection
To provide an optimal solution for blood collection, Greiner Bio-One has developed the new VACUETTE® SAFELINK Holder. This sterile tube holder provides a safe, needleless option for blood collection procedures from a female luer port. The VACUETTE® SAFELINK provides a secure luer lock connection, making this holder a safe and easy-to-use accessory for transfer of... Read more
Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Basel, 05 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared... Read more